Anti-TA-MUC1 monoclonal antibody - Glycotope

Drug Profile

Anti-TA-MUC1 monoclonal antibody - Glycotope

Alternative Names: GlycoOptimised IgG1 antibody - Glycotope; GT-MAB 2.5-GEX™; PankoMab; PankoMab-GEX; Trifunctional antibody - Glycotope

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NEMOD Biotherapeutics [CEASED]
  • Developer Glycotope
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Mucin 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Ovarian cancer
  • Phase I Solid tumours

Most Recent Events

  • 30 Oct 2017 Daiichi Sankyo Company and Glycotope sign an option agreement for Anti-TA-MUC1 monoclonal antibody collaboration and licensing
  • 27 Sep 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (AACR-2017)
  • 08 Mar 2016 Anti-TA-MUC1 monoclonal antibody is still in phase II trials in Ovarian cancer (Recurrent, Maintenance therapy) in Germany, Hungary, Italy, Poland, Romania, Russia, Spain and United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top